Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Lung Neoplasms 2 Refractory/Relapse Neuroblastoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteoporosis 1 Neuroendocrine Tumors 1 Neoplasms, Squamous Cell 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma 1 Infertility 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Breast Neoplasms 1

Interventions

Nivolumab 146 Ipilimumab 137 pembrolizumab 122 Cyclophosphamide 78 Interleukin-2 69 aldesleukin 63 Temozolomide 46 trametinib 37 Radiosurgery 37 Vemurafenib 36 fludarabine 34 Biopsy 34 dabrafenib 33 Radiotherapy 33 Blood Specimen Collection 31 fludarabine phosphate 30 sargramostim 27 Bevacizumab 27 Introns 23 Dacarbazine 22 Magnetic Resonance Spectroscopy 21 CTLA-4 Antigen 20 encorafenib 19 cobimetinib 19 binimetinib 19 Specimen Handling 19 Paclitaxel 19 Granulocyte-Macrophage Colony-Stimulating Factor 19 Cisplatin 17 incomplete Freund's adjuvant 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma × Biological Products × Clear all

NCT02828202 2025-02-11

MelBase

Assistance Publique - Hôpitaux de Paris

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡